Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
26 Apr 2021
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
12 Mar 2021
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
12 Jan 2021
Ingelheim, Germany and Oxford and London, UK, January 12th, 2021 – Boehringer Ingelheim and Enara Bio.
PHESI AND SENSYNE PARTNERSHIP EXPANDS CLINICAL DEVELOPMENT CAPABILITIES AND SOLUTIONS
5 Jan 2021
The investment will be used to accelerate Phesi's and Sensyne's product roadmaps.
DyNAbind and Salipro Biotech Enter Collaboration Agreement
9 Dec 2020
DyNAbind GmbH and Salipro Biotech AB are teaming up to tackle drug discovery against challenging membrane protein targets!
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
3 Dec 2020
The acquisition will establish a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets.
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
2 Dec 2020
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
17 Nov 2020
SAN RAFAEL and TORONTO, Nov. 17, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need.
Novartis Announces Collaboration with Molecular Partners to Develop Two DARPin® Therapies Designed for Potential Use Against COVID-19
28 Oct 2020
Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.
Proteros Biostructures and X-Chem to Offer Comprehensive Joint Target-to-Lead Drug Discovery Services
1 Oct 2020
Proteros Biostructures GmbH (Proteros) and X-Chem, Inc. (X-Chem) announced today the launch of an alliance with the goal of offering Hit-Identification and Target-to-Lead drug discovery services based on their complementary technology platforms.
Join Our Newsletter for Free
